Company intelligence / Profile preview
Mochida Pharmaceutical Co., Ltd.
- Ownership
- Public · 4534
- Employees
- ~1522
- Development stage
- Commercial
Overview
Mochida Pharmaceutical has a long history of developing and commercializing innovative pharmaceuticals in Japan. Recent clinical results include regulatory approval for new indications such as TREPROST Inhalation Solution for pulmonary hypertension associated with interstitial lung disease. The company continues to expand its pipeline through internal R&D and strategic partnerships.
- Therapeutic areas
- GastroenterologyPulmonologyPsychiatryWomen's HealthNeurology
- Modalities
- Small moleculesbiologicsbiomaterials
- Industry
- Biotech
Drug pipeline
8 assets7 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $707.4M
- Total revenue
- $739.3M
- Enterprise value
- $596.1M
Beyond the preview
Go deeper on Mochida Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mochida Pharmaceutical Co., Ltd..